They were also compared new anti-TNF-α therapy patients to historical data from 398 patients who started on originator IFX in a prior United Kingdom IBD biologics audit (2011–2015) and they were found no significant differences in clinical response and remission rates at the same timepoint (Lynch et al., 2013; Russell et al., 2013). This evidence concerns the gene TNF and inflammatory bowel disease.